News
Zacks Investment Research on MSN4h
AMGN's Key Drugs Repatha, Evenity & Blincyto Drive Q1 Sales GrowthAmgen AMGN is off to a strong start in 2025 with its first-quarter earnings as well as sales beating estimates. Particularly, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback